Rezolute, Inc. (RZLT) Minute Stock Prediction

About:

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

23

Address:

Rezolute, Inc. 201 Redwood Shores Parkway Suite 315 Redwood City CA 94065 United States

Website:

Home

Phone:

650-206-4507